Inclusion Criteria:

        Patients must meet all the following inclusion criteria within 21 days of study
        participation (Cycle 1, Day 1) in order to be eligible to participate in the study:

          1. Are ≥18 years old males or females.

          2. Are capable of understanding and have voluntarily signed the informed consent document
             and willing to comply with study requirements.

          3. Have histologically or cytologically confirmed diagnostic of metastatic cancer or
             advanced-stage solid tumor that has progressed following standard therapy or for
             which, in the opinion of the Investigator, no standard effective therapy is available
             or the patient has a contraindication to or declines standard therapy.

          4. Have measurable disease according to the Response Evaluation Criteria in Solid Tumors
             (RECIST 1.1).

          5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          6. Have an expected survival of at least 3 months.

          7. Have a negative pregnancy test result at screening confirmed by a serum beta-human
             chorionic gonadotropin (β-HCG) (for women of childbearing potential (WOCBP); not
             applicable to patients who are unable to become pregnant, including those with
             bilateral oophorectomy, salpingectomy and/or hysterectomy or postmenopausal [no menses
             for the previous 12 months]) or those that have had definitive radiation therapy to
             the pelvis. The test must be performed within 1 week before Day 1 of treatment.

          8. WOCBP who are sexually active with a nonsterilised male partner (sterilised males
             should be ≥1 year postvasectomy and have confirmed that they have obtained
             documentation of the absence of sperm in the ejaculate) and male patients whose sexual
             partners are WOCBP should agree to remain abstinent (refrain from heterosexual
             intercourse) or use 2 effective methods of contraception, including at least 1 method
             with a failure rate of <1% per year, during the treatment period and for at least 6
             months and 3 months for female and male patients, respectively, following the last
             dose of TH1902.

             • Effective contraceptive measures include the following:

               -  Intrauterine device (e.g. IUD) plus one barrier method.

               -  Oral, implantable or injectable contraceptive plus one barrier method.

               -  Two barrier methods. Effective barrier methods are male or female condoms,
                  diaphragms and spermicides (cream or gel that contains a chemical to kill sperm).

          9. WOCBP must agree to not donate ova and agree to ongoing pregnancy testing during the
             course of the study and 6 months following the last dose of TH1902. Male patients must
             refrain from donating sperm during the course of the study and 3 months following the
             last dose of TH1902.

         10. Male patients with pregnant female partners, must agree to remain abstinent or use a
             condom (latex condom is recommended) during the treatment period and for at least 3
             months after the last dose of TH1902 to avoid exposing the embryo, even if he has
             undergone a successful vasectomy.

         11. Patients with HIV/HBV/HBC will not be excluded from entry into the study provided the
             following criteria are met:

               -  Patients with HIV infection must have CD4+ T-cell (CD4+) counts ≥ 350 cells/µL.

               -  The following eligibility criteria are for patients with evidence of chronic HBV
                  infection or patients with history of chronic HCV or who are virologically
                  suppressed on HCV treatment

                    -  Liver-related laboratory eligibility criteria should be the same as that for
                       the general population.

                    -  Exceptions: AST/ALT and bilirubin criteria may be less stringent in patients
                       with cancers such as hepatocellular carcinoma and cholangiocarcinoma in whom
                       hepatic function based on Child-Pugh score should be used.

                    -  Patients with chronic HBV infection with active disease who meet the
                       criteria for anti HBV therapy should be on a suppressive antiviral therapy
                       prior to initiation of cancer therapy.

                    -  Patients on concurrent HCV treatments must have HCV below the limit of
                       quantification.

                    -  Patients with untreated HCV may be enrolled if the HCV is stable, the
                       patient is not at risk for hepatic decompensation, and the investigational
                       cancer treatment is not expected to exacerbate the HCV infection.

               -  Patients with chronic HBV infection with active disease who meet the criteria for
                  anti HBV therapy should be on a suppressive antiviral therapy prior to initiation
                  of cancer therapy.

               -  Patients with a history of HCV infection should have completed curative antiviral
                  treatment and HCV viral load must be below the limit of quantification. For
                  incurable cancers, patients with untreated HCV may be enrolled if the HCV is
                  stable, the patient is not at risk for hepatic decompensation, and the
                  investigational cancer treatment is not expected to exacerbate the HCV infection.

        Patients must meet the following additional criterion to enter in Part 2:

        1. Histologically or cytologically confirmed TNBC, gynecological cancer (epithelial ovarian
        or endometrial cancer), colorectal cancer, or pancreatic cancer, and for which no standard
        effective therapy is available.

        Exclusion Criteria:

        Patients who meet any one of the following criteria at baseline will be excluded from study
        participation:

          1. Have received chemotherapy, biologic therapy, immunotherapy, radiotherapy (except
             palliative radiation delivered to <20% of bone marrow), or investigational agents
             within 4 weeks before the first dose of study drug. Patients who have received
             targeted therapy (investigational or approved) will not have received their last dose
             within 4 weeks, or within 5 half-lives (whichever is shorter).

          2. Have known hypersensitivity to docetaxel or to any excipients in the TH1902
             investigational medicinal product (IMP) (e.g. polysorbate 80, predominantly known as
             Tween® 80).

          3. Have severe toxicity with previous taxane treatment.

          4. Any past or current history of brain, leptomeningeal or spinal metastases.

          5. Are pregnant or breastfeeding.

          6. Had any acute viral (including COVID-19), bacterial, or fungal infection that requires
             parenteral therapy within 14 days prior to study treatment (Cycle 1, Day 1).

          7. Have received a live vaccine within 30 days prior to administration of the IMP.

          8. Had treatment with cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C8 (CYP2C8)
             enzyme-inducing or enzyme inhibiting drugs within 14 days prior to treatment with the
             IP (Cycle 1 Day 1) (Refer to Appendix 3).

          9. Have any of the following hematologic abnormalities at baseline:

               -  Hemoglobin <9.0 g/dL (90 g/L)*

               -  ANC <1.5 x 109/L (1500/mm3)

               -  Platelet count <100 x 109/L (100,000/mm3) *Patients may be transfused with packed
                  red blood cells prior to TH1902 infusion, if clinically warranted. A
                  post-transfusion hemoglobin assessment may qualify the patient for participation.

         10. Have any of the following serum chemistry abnormalities at baseline:

               -  Bilirubin >ULN.

               -  ALK Phos >2.5 with an aspartate aminotransferase (AST) and/or alanine
                  aminotransferase (ALT) >1.5 times the ULRR, or >5 times ULRR for patients with
                  documented liver metastases.

               -  Serum calcium above ULRR.

               -  Creatinine clearance (calculated according to the Cockcroft & Gault formula
                  (Cockcroft, 1976)) < 60 mL/ min):

                    -  Female CrCl = (140 - age in years) × weight in kg × 0.85 / (serum creatinine
                       in mg/dL x 72)

                    -  Male CrCL = (140 - age in years) × weight in kg × 1.00 / (serum creatinine
                       in mg/dL x 72)

         11. Baseline corrected interval between Q and T waves on electrocardiogram (ECG) (QTc) ≥
             470 msec using Fridericia's formula.

         12. Have unstable or uncompensated respiratory, cardiac, hepatic or renal disease or any
             other organ system dysfunction, medical condition, or laboratory abnormality which, in
             the opinion of the Investigator, would either compromise the patient's safety or
             interfere with the evaluation of the IMP.

         13. Have evidence of persistent grade 2 or greather neurotoxicity.